Navigation Links
Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Date:1/3/2012

AMSTERDAM, January 4, 2012 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its gene therapy program for the treatment of hemophilia B. Orphan designation in the U.S. could provide up to seven years market exclusivity on regulatory approval. Orphan designation for AMT's hemophilia program in the European Union was granted in November 2011.

AMT's hemophilia B program, which consists of an adeno-associated viral (AAV) vector containing the human factor IX gene, is being investigated in a Phase I/II study conducted by St. Jude's Children's Research Hospital (Memphis, USA) and University College London (UK). Promising data from an initial 6 patients, recently published in the New England Journal of Medicine (N Engl J Med 2011; 365:2357-2365), shows that gene therapy administration resulted in a reduced need for protein replacement treatment, the standard care for hemophilia patients.  AMT is preparing for additional clinical development work to establish safety, tolerability and proof-of-concept with a factor IX gene therapy produced using its proprietary AAV production system.

"U.S. orphan designation provides additional support for our hemophilia B gene therapy program and supplements the designation in the EU received in November," said Jörn Aldag, CEO of AMT. "The early clinical success seen with the program to date by our partners is very encouraging. We will build on this success in the coming months."  

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. AMT has a product pipeline of gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicl
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Tornado-Torn ... Health Care Facility, MALVERN, Pa., Jan. ... a devastating 2007 tornado,Siemens has announced that, as part of its ... new MAGNETOM ESSENZA, worth,approximately $800,000., Siemens took notice of Sumter,s ...
... talent and investors to state, TOPEKA, Kan., ... announced today a "Come Home to Kansas" initiative ... investors to Kansas. Partners in this project include ... the Kansas,Bioscience Organization and the KTEC PIPELINE., ...
... Inc.,(Nasdaq: CRDC ) today reported financial results ... and six months ended December 31, 2007., ... over 1,000,C-Port systems shipped in the past quarter ... to enable minimally-invasive cardiac surgery and,substantial advancement for ...
Cached Biology Technology:A Magnetic Gift: Sumter Regional Hospital Receives New MRI as Charitable Donation From Siemens 2'Come Home to Kansas' Announced by KTEC 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 3Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 4Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 5Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 6Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 7
(Date:4/18/2014)... emergency contraceptive pills in Peru found that 28 ... substandard quality or falsified. Many pills released the ... active ingredient. One batch had no active ingredient ... drugs, researchers at the Georgia Institute of Technology ... quickly assess suspected counterfeit drugs and then characterize ...
(Date:4/18/2014)... Ancient DNA adds a twist to the story of how ... published April 21 in the journal Proceedings of the ... bones of chickens that lived 200-2300 years ago in Europe, ... chickens may have looked far different from the chickens we ... traits we associate with modern domestic chickens -- such as ...
(Date:4/17/2014)... 17 In the most densely forested and most ... two centuries of human needs, values and practices. Disturbances ... forests for agriculture and development, have set the stage ... Forest Service study reports. , The report Five ... management needs in the Northern United States ...
Breaking Biology News(10 mins):Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Ancient DNA offers clues to how barnyard chickens came to be 2Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3
... MANHATTAN, Kan. -- If cats really had nine lives, one ... of diseases that threaten feline health. Yunjeong Kim, a ... Kansas State University, has developed a research approach that tackles ... work is being supported by a $156,342 award from the ...
... ensure that the benefits of genetic resources are shared in ... the Convention on Biological Diversity, though questions remain about how ... new report from the Synthetic Biology Project at the Woodrow ... may affect U.S. researchers working in the field of synthetic ...
... (4 November 2013) The Population Council, an international ... development issues, will present findings from more than 40 ... Addis Ababa, Ethiopia (November 12-15, 2013). Notable ... in programs that strengthen gender equity; improve financing mechanisms ...
Cached Biology News:College of Veterinary Medicine researcher doubles down on deadly, infectious cat diseases 2College of Veterinary Medicine researcher doubles down on deadly, infectious cat diseases 3Population Council to present more than 40 studies at International Conference on Family Planning 2Population Council to present more than 40 studies at International Conference on Family Planning 3Population Council to present more than 40 studies at International Conference on Family Planning 4
MOUSE ANTI RAT RT1Bu Immunogen: Rat thymocyte membrane glycoproteins...
RABBIT ANTI HUMAN CYTOCHROME P450 1A1/2 Immunogen: Purified human CYP1A2 expressed in E.Coli ...
RABBIT ANTI HUMAN APP (KP1 DOMAIN) Immunogen: Synthetic peptide composed of amino acids 292-312 from the KPI domain of human APP....
... The Light Diagnostics Cytomegalovirus (CMV) pp65 Antigenemia ... qualitative identification of lower matrix protein pp65 ... Kit Components: ... One bottle containing 220 mL of buffered ...
Biology Products: